FOXP3 and ganglioneuroblastoma: In addition, percentages of PD‐L1 and FoxP3 positive cells per all analyzed cells in ganglioneuroblastoma (the investigated indication with the highest median values) were respectively equivalent only to 8.5 and 9.1% of the median of PD‐L1 and FoxP3 reported in similar NSCLC DIA 15; an indication approved for anti‐PD‐1/PD‐L1 immunotherapies, and the only one with published digital pathology data to allow us to put our pediatric results in perspective.